Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04123470 | A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | PHASE1 | COMPLETED | 24 | — | — | Jan 28, 2020 | Jul 30, 2023 | Sep 19, 2024 | 3 | United States, Sweden |
The AE reporting period begins upon receiving the first LOAd703 and/or atezolizumab treatment and continues until final visit at week 57
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | Delolimogene mupadenorepvec plus atezolizumab |
| Name | Type | Description |
|---|---|---|
| delolimogene mupadenorepvec | GENETIC | LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL |
| atezolizumab | BIOLOGICAL | Atezolizumab is an anti-PD-L1 antibody |
Inclusion Criteria: 1. Pathological confirmation of melanoma. 2. A life expectancy of at least 3 months as per the investigator 3. Valid for Swedish patients: Patients has locally advanced melanoma or metastatic melanoma, but not eligible for complete resection of melanoma Valid for US patients: Pa...